High dose combination radiotherapy for the treatment of localized prostate cancer

Journal of Urology

Volumn 160, Issue 1, 1998, Pages 91-96

  Zeitlin, Scott I ^a   Sherman, Joel ^a   Raboy, Adley ^a   Lederman, Gil ^a   Albert, Peter ^a  

^a NONE

Author keywords

Brachytherapy; Prostate neoplasms; Radiotherapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN RELEASE; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; SCORING SYSTEM; URETHRA STRICTURE; URINE RETENTION;

EID: 0032323468     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63042-8     Document Type: Article

References (22)

1. Mettlin, C. J., Murphy, G. P., Ho, R. and Menck, H. R.: The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer, 77: 2162, 1996.
2. Raboy, A., Adler, H. and Albert, P.: Extraperitoneal endoscopic pelvic lymph node dissection: a review of 125 patients. J. Urol., 158: 2202, 1997.
3. Porter, A. T., Blasko, J. C., Grimm, P. D., Reddy, S. M. and Ragde, H.: Brachytherapy for prostate cancer. CA, 45: 165, 1995.
4. Whitmore, W. F., Jr., Hilaris, B. and Grabstald, H.: Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J. Urol., 108: 918, 1972.
5. Holm, H. H., Juul, J. F., Pedersen, H. H., Hanson, H. and Stroyer, I.: Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol., 130: 283, 1983.
6. Fuks, Z., Leibel, S. A., Wallner, K. E., Begg, C. B., Fair, W. R., Anderson, L. L., Hilaris, B. S. and Whitmore, W. F.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int. J. Rad. Oncol. Biol. Physiol., 21: 537, 1991.
7. Stamey, T. A., Ferrari, M. K. and Schmid, H. -P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol., 150: 1856, 1993.
8. Patel, J., Worthen, R., Abadir, R., Weaver, D. J., Weinstein, S. and Ross, G., Jr.: Late results of combined iodine-125 and external beam radiotherapy in carcinoma of the prostate. Urology, 36: 27, 1990.
9. Iversen, P., Rasmussen, F. and Holm, H. H.: Long-term results of ultrasonically guided implantation of 125-I seeds combined with external irradiation in localized prostatic cancer. Scand. J. Urol. Nephrol., suppl., 138: 109, 1991.
10. Critz, F. A., Tarlton, R. S. and Holladay, D. A.: Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation. Cancer, 75: 2383, 1995.
11. Critz, F. A., Levinson, A. K., Williams, W. H. and Holladay, D. A.: Prostate specific antigen nadir: the optimum level after irradiation for prostate cancer. J. Clin. Oncol., 14: 2893, 1996.
12. 125 iodine implantation for localized prostate cancer using percutaneous approach. J. Urol., 153: 1020, 1995.
13. Dattoli, M., Wallner, K., Sorace, R., Koval, J., Cash, J., Acosta, R., Brown, C., Etheridge, J., Binder, M., Brunelle, R., Kirwan, N., Sanchez, S., Stein, D. and Wasserman, S.: 103Pd brachy-therapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int. J. Rad. Oncol. Bio. Physiol., 35: 875, 1996.
14. Blasko, J. C., Grimm, P. D. and Ragde, H.: External beam irradiation with palladium-103 implantation for prostate carcinoma. Int. J. Rad. Oncol. Bio. Physiol., 30: 219, 1994.
15. Zelefsky, M. J., Leibel, S. A., Wallner, K. E., Whitmore, W. F., Jr. and Fuks, Z.: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J. Clin. Oncol., 13: 459, 1995.
16. Lee, W. R., Hanks, G. E., Schultheiss, T. E., Corn, B. W. and Hunt, M. A.: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol., 13: 464, 1995.
17. Wallner, K., Roy, J. and Harrison, L.: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J. Clin. Oncol., 14: 449, 1996.
18. Cox, J. D. and Stoffel, T. J.: The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. Cancer, 40: 156, 1977.
19. Schellhammer, P. F., Ladaga, L. E. and El-Mahdi, A.: Histological characteristics of prostatic biopsies after 125 iodine implantation. J. Urol., 123: 700, 1980.
20. Steiner, M. S., Morton, R. A. and Walsh, P. C.: Impact of anatomical radical prostatectomy on urinary continence. J. Urol., 145: 512, 1991.
21. Blasko, J. C., Ragde, H. and Grimm, P. D.: Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand. J. Urol. Nephrol., suppl., 137: 113, 1991.
22. Catalona, W. J. and Bigg, S. W.: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol., 143: 538, 1990.